{"DataElement":{"publicId":"2688964","version":"2","preferredName":"Other Malignant Neoplasm Transplantation Time Status Other Malignant Neoplasm Status Type","preferredDefinition":"Information related to the status of the other malignancy at the time of transplantation.","longName":"OTHR_MLG_TRN_ST_TP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2688953","version":"1","preferredName":"Other Malignant Neoplasm Transplantation Time Status","preferredDefinition":"Not otherwise specified._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas._The grafting of tissues from one individual to another or place to place within a single individual._The continuum of experience in which events pass from the future through the present to the past._A condition or state at a particular time.","longName":"OTHR_MLG_TRN_ST","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2660471","version":"1","preferredName":"Other Malignant Neoplasm","preferredDefinition":"Not otherwise specified.:A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","longName":"C17649:C9305","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"33E5C497-ED80-4C81-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2007-06-27","modifiedBy":"ONEDATA","dateModified":"2007-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2674595","version":"1","preferredName":"Transplantation Time Status","preferredDefinition":"The grafting of tissues from one individual to another or place to place within a single individual.:the continuum of experience in which events pass from the future through the present to the past.:A condition or state at a particular time.","longName":"C15342:C25207:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Time","conceptCode":"C25207","definition":"The continuum of experience in which events pass from the future through the present to the past.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"384B648C-219F-1050-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-22","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-22","modifiedBy":"ONEDATA","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4D0BA7-F3F8-1228-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2688958","version":"1.1","preferredName":"Other Malignant Neoplasm Status Type","preferredDefinition":"Different than the one(s) previously specified or mentioned._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas._A condition or state at a particular time._Something distinguishable as an identifiable class based on common qualities.","longName":"OTHR_MALG_ST_TP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"36","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Relapse (untreated)","valueDescription":"Without Therapeutic Procedure Recurrent Disease","ValueMeaning":{"publicId":"2688887","version":"1","preferredName":"Without Therapeutic Procedure Recurrent Disease","longName":"2688887","preferredDefinition":"Used to indicate the absence or lack of something or someone. (from Merriam-Webster OnLine): An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: the return of a sign, symptom, or disease after a remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4ABC47-79F8-3D22-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83C0E1E6-4D4F-4E7F-E040-BB89AD436A4A","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2010-04-08","modifiedBy":"ONEDATA","dateModified":"2010-04-08","deletedIndicator":"No"},{"value":"PR","valueDescription":"Partial response (PR)","ValueMeaning":{"publicId":"3056056","version":"1","preferredName":"Partial response (PR)","longName":"3056056","preferredDefinition":"At least 30% decrease in the sum of the longest diameter of measured lesions\r\n(target lesions) taking as reference the baseline sum of longest diameters.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83C0E1E6-4E28-4E7F-E040-BB89AD436A4A","latestVersionIndicator":"Yes","beginDate":"2010-04-08","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83C19E03-C1C0-B693-E040-BB89AD43571B","beginDate":"2010-04-08","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-04-08","modifiedBy":"ONEDATA","dateModified":"2010-04-08","deletedIndicator":"No"},{"value":"PD","valueDescription":"Progressive disease (PD)","ValueMeaning":{"publicId":"3056054","version":"1","preferredName":"Progressive disease (PD)","longName":"3056054","preferredDefinition":"At least a 20% increase in the sum of the longest diameter of measured\r\nlesions (target lesions), taking as reference the smallest sum of the longest diameters recorded since the treatment started of the appearance of one or more new lesions.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83C0E1E6-4DE2-4E7F-E040-BB89AD436A4A","latestVersionIndicator":"Yes","beginDate":"2010-04-08","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83C19E03-C1D4-B693-E040-BB89AD43571B","beginDate":"2010-04-08","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-04-08","modifiedBy":"ONEDATA","dateModified":"2010-04-08","deletedIndicator":"No"},{"value":"CR","valueDescription":"Complete response (CR)","ValueMeaning":{"publicId":"3056058","version":"1","preferredName":"Complete response (CR)","longName":"3056058","preferredDefinition":"Disappearance of all target lesions for a period of at least one month.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83C0E1E6-4E6D-4E7F-E040-BB89AD436A4A","latestVersionIndicator":"Yes","beginDate":"2010-04-08","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83C19E03-C1AC-B693-E040-BB89AD43571B","beginDate":"2010-04-08","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-04-08","modifiedBy":"ONEDATA","dateModified":"2010-04-08","deletedIndicator":"No"},{"value":"CRU","valueDescription":"CRU","ValueMeaning":{"publicId":"3056057","version":"1","preferredName":"CRU","longName":"3056057","preferredDefinition":"Complete response with persistent imaging abnormalities of unknown signficance","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83C0E1E6-4E4A-4E7F-E040-BB89AD436A4A","latestVersionIndicator":"Yes","beginDate":"2010-04-08","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83C0E1E6-4E63-4E7F-E040-BB89AD436A4A","beginDate":"2010-04-08","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-04-08","modifiedBy":"ONEDATA","dateModified":"2010-04-08","deletedIndicator":"No"},{"value":"NR/SD","valueDescription":"Stable disease (NR/SD)","ValueMeaning":{"publicId":"3056055","version":"1","preferredName":"Stable disease (NR/SD)","longName":"3056055","preferredDefinition":"Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify\r\nfor PD taking as reference the smallest sum of the longest diameters since the treatment started.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83C0E1E6-4E05-4E7F-E040-BB89AD436A4A","latestVersionIndicator":"Yes","beginDate":"2010-04-08","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83C19E03-C1E8-B693-E040-BB89AD43571B","beginDate":"2010-04-08","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-04-08","modifiedBy":"ONEDATA","dateModified":"2010-04-08","deletedIndicator":"No"},{"value":"Adjuvant","valueDescription":"Adjuvant Therapy","ValueMeaning":{"publicId":"2567165","version":"1","preferredName":"Adjuvant Therapy","longName":"2567165","preferredDefinition":"Any therapy that is administered to augment or stimulate other treatment modalities or to minimize or prevent disease recurrence subsequent to the main treatment plan. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adjuvant Therapy","conceptCode":"C15675","definition":"Any therapy that is administered to augment or stimulate other treatment modalities or to minimize or prevent disease recurrence subsequent to the main treatment plan.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-11-05","modifiedBy":"COOPERM","dateModified":"2017-04-11","changeDescription":"Updated definition to match current NCIt. mc 4/11/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83C0E1E6-4D8B-4E7F-E040-BB89AD436A4A","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2010-04-08","modifiedBy":"ONEDATA","dateModified":"2010-04-08","deletedIndicator":"No"},{"value":"Never treated","valueDescription":"Never Therapeutic Procedure","ValueMeaning":{"publicId":"2685077","version":"1","preferredName":"Never Therapeutic Procedure","longName":"2685077","preferredDefinition":"Not ever; at no time in the past (or future).: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Never","conceptCode":"C70543","definition":"Not ever; at no time in the past (or future).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B83BB14-A509-653C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-02","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83C0E1E6-4D95-4E7F-E040-BB89AD436A4A","beginDate":"2008-01-22","endDate":null,"createdBy":"ALEYR","dateCreated":"2010-04-08","modifiedBy":"ONEDATA","dateModified":"2010-04-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2688957","version":"1","preferredName":"Other Malignant Neoplasm Status Type","preferredDefinition":"Not otherwise specified.:A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004:A condition or state at a particular time.:Type; a subdivision of a particular kind of thing.","longName":"C17649:C9305:C25688:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4D0BA7-F410-1228-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"ONEDATA","dateModified":"2007-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"83C0E1E6-4D38-4E7F-E040-BB89AD436A4A","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2010-04-08","modifiedBy":"NYCHM","dateModified":"2010-04-09","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964924","version":"1","longName":"2400r1: Pre-TED","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"pre_ted_omalig_stat_hsct","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:diseaseStatusCode ","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the status of the ot","type":"Preferred Question Text","description":"What was the status of the other malignancy at the time of transplantation?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2688964","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.diseaseStatusCode WHERE PerformedDiagnosis.value = {other malignancy} AND PerformedDiagnosis > PerformedObservation.dateRange IS LESS THAN OR EQUAL TO PerformedSubstanceAdministration.dateRange AND PerformedSubstanceAdministration > DefinedSubstanceAdministration.nameCode = \"Administer Hematopoietic Cell Product {Transplantation}\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"83C0E1E6-4E8F-4E7F-E040-BB89AD436A4A","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-04-08","modifiedBy":"KUMMEROA","dateModified":"2021-08-06","changeDescription":". 2021-8-6 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}